COMPANY PROFILE // THE 014 REPORT
BioAtla, Inc.
BCAB (OTC)
Assembled from 1 government source in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber3 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-09-29: a pattern of leadership change.
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2026-08-28 and 3 more times (last 24 months).
✓ SEC filings✓ State registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no website, no lobbying registration on record.
BioAtla, Inc. is an SEC-registered operating company in biological products, (no diagnostic substances), incorporated in DE, based in San Diego, CA; listed as BCAB (OTC).[source] It has filed 57 documents with the SEC in the last 12 months; the latest is Form 10-Q, filed 2026-11-16.[source] Seraphix flags 2 items from these records: 8-K Item 3.01 filed; 3 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-09-29.[source]
- red0
- amber2
- info0
- CLEAR25
- POSSIBLE MATCH1
- MATCH0
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- SHORT JAY M PHD · Chief Executive Officer (Director,Officer) · latest Form 4 2026-03-12 · filing · LinkedIn search
- Sievers Eric · Chief Medical Officer (Officer) · latest Form 4 2026-03-12 · filing · LinkedIn search
- Vasquez Christian · Chief Financial Officer (Officer) · latest Form 4 2026-03-12 · filing · LinkedIn search
- WALDRON RICHARD A · Former Chief Financial Officer (Officer) · latest Form 4 2026-03-02 · filing · LinkedIn search
- GRAY MARY ANN · Director · latest Form 4 2025-06-18 · filing · LinkedIn search
- MCBRINN SYLVIA · Director · latest Form 4 2025-06-18 · filing · LinkedIn search
- Moran Susan · Director · latest Form 4 2025-06-18 · filing · LinkedIn search
- STEINMAN LAWRENCE · Director · latest Form 4 2025-06-18 · filing · LinkedIn search
- Smith Scott Andrew · Director · latest Form 4 2025-06-18 · filing · LinkedIn search
- Williams Eddie · Director · latest Form 4 2025-06-18 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001826892 | source |
| EIN | 85-1922320 | source |
| Business address (SEC) | 11085 TORREYANA ROAD, SAN DIEGO, CA, 92121 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- AMGEN INC · 123 SEC filings in 12 months · 1 flag · $507.4M federal (possible match)
- Vir Biotechnology, Inc. · 117 SEC filings in 12 months · 1 flag · $65.9M federal (possible match)
- Vericel Corp · 109 SEC filings in 12 months · 1 flag · $37.3M federal (possible match)
- Coherus Oncology, Inc. · 53 SEC filings in 12 months · 3 flags · $11.8M federal (possible match)
- BIO-TECHNE Corp · 77 SEC filings in 12 months · 1 flag · $6.6M federal (possible match)
- Twist Bioscience Corp · 337 SEC filings in 12 months · 2 flags · $5.9M federal (possible match)
- Adaptive Biotechnologies Corp · 185 SEC filings in 12 months · 1 flag · $1.9M federal (possible match)
- AGENUS INC · 82 SEC filings in 12 months · 3 flags · $613K federal (possible match)
- REPLIGEN CORP · 89 SEC filings in 12 months · 1 flag · $457K federal (possible match)
- Revolution Medicines, Inc. · 171 SEC filings in 12 months · 2 flags · $15K federal (possible match)
- RECURSION PHARMACEUTICALS, INC. · 174 SEC filings in 12 months · 1 flag
- GILEAD SCIENCES, INC. · 173 SEC filings in 12 months
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Keros Therapeutics, Inc. · GRAY MARY ANN
- Compass Therapeutics, Inc. · GRAY MARY ANN
- CRESCENT BIOPHARMA, INC. · Moran Susan
- Tyra Biosciences, Inc. · Moran Susan
- FORUM MARKETS Inc · STEINMAN LAWRENCE
- Pasithea Therapeutics Corp. · STEINMAN LAWRENCE
- Viatris Inc · Smith Scott Andrew
- Tessera Defense & Homeland Security Inc. · Williams Eddie
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-16 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-10-29 filing EFFECT · SEC EDGAR
- 2026-10-29 filing 424B3 · SEC EDGAR
- 2026-10-27 filing RW · SEC EDGAR
- 2026-10-20 filing Registration (S-1) · SEC EDGAR
- 2026-10-20 filing 8-K items 1.01,1.02,3.02,9.01 · SEC EDGAR
- 2026-09-29 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-08-28 filing 8-K items 3.01 · SEC EDGAR
- 2026-08-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-07-16 filing 8-K items 5.07 · SEC EDGAR
- 2026-06-03 filing ARS · SEC EDGAR
- 2026-06-03 filing DEFA14A · SEC EDGAR
- 2026-06-03 filing Proxy statement · SEC EDGAR
- 2026-05-15 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-04-29 filing 10-K/A · SEC EDGAR
- 2026-04-02 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-03-31 filing S-8 · SEC EDGAR
- 2026-03-31 filing Annual report (10-K) · SEC EDGAR
- 2026-03-31 filing 8-K items 2.02,7.01 · SEC EDGAR
- 2026-03-23 officer change 8-K items 5.02,5.07 · SEC EDGAR
- 2026-03-20 filing 424B2 · SEC EDGAR
- 2026-03-13 filing 424B2 · SEC EDGAR
- 2026-03-09 filing 424B2 · SEC EDGAR
- 2026-03-02 filing DEFA14A · SEC EDGAR
- 2026-03-02 officer change 8-K items 2.02,2.05,5.02,7.01,8.01,9.01 · SEC EDGAR
- 2026-02-11 filing DEFM14A · SEC EDGAR
- 2026-02-09 filing 8-K items 8.01 · SEC EDGAR
- 2026-02-06 filing 8-K items 3.01,7.01 · SEC EDGAR
- 2026-01-30 filing PREM14A · SEC EDGAR
- 2026-01-30 filing 8-K items 5.03,5.07,7.01,8.01,9.01 · SEC EDGAR
120 earlier entries
- 2026-01-16 filing S-3
- 2026-01-15 filing DEFA14A
- 2026-01-12 filing 8-K items 3.02,5.03,5.07,8.01,9.01
- 2025-12-31 filing DEFA14A
- 2025-12-31 filing 8-K items 1.01,3.02,7.01,9.01
- 2025-12-30 filing 8-K items 5.07,8.01
- 2025-12-05 filing Proxy statement
- 2025-11-24 filing PRE 14A
- 2025-11-21 filing 424B5
- 2025-11-21 filing 8-K items 1.01,2.03,9.01
- 2025-11-13 filing Quarterly report (10-Q)
- 2025-11-13 filing 8-K items 2.02,9.01
- 2025-09-22 filing 8-K items 8.01
- 2025-08-07 filing Quarterly report (10-Q)
- 2025-08-07 filing 8-K items 2.02,9.01
- 2025-06-20 officer change 8-K items 5.02,5.07
- 2025-06-18 insider First Form 3/4/5 on record for GRAY MARY ANN (Director)
- 2025-06-18 insider First Form 3/4/5 on record for MCBRINN SYLVIA (Director)
- 2025-06-18 insider First Form 3/4/5 on record for Moran Susan (Director)
- 2025-06-18 insider First Form 3/4/5 on record for STEINMAN LAWRENCE (Director)
- 2025-06-18 insider First Form 3/4/5 on record for Smith Scott Andrew (Director)
- 2025-06-18 insider First Form 3/4/5 on record for Williams Eddie (Director)
- 2025-06-03 insider First Form 3/4/5 on record for SHORT JAY M PHD (Chief Executive Officer)
- 2025-06-03 insider First Form 3/4/5 on record for Sievers Eric (Chief Medical Officer)
- 2025-06-03 insider First Form 3/4/5 on record for Vasquez Christian (Chief Financial Officer)
- 2025-06-03 insider First Form 3/4/5 on record for WALDRON RICHARD A (Former Chief Financial Officer)
- 2025-05-16 filing 8-K items 3.01
- 2025-05-16 filing 424B3
- 2025-05-14 filing EFFECT
- 2025-05-12 filing CORRESP
- 2025-05-09 filing UPLOAD
- 2025-05-06 filing S-3
- 2025-05-06 filing Quarterly report (10-Q)
- 2025-05-06 filing 8-K items 2.02,9.01
- 2025-04-24 filing ARS
- 2025-04-24 filing DEFA14A
- 2025-04-24 filing Proxy statement
- 2025-03-28 filing S-8
- 2025-03-28 filing Annual report (10-K)
- 2025-03-27 filing 8-K items 2.02,2.05,9.01
- 2025-03-14 officer change 8-K items 5.02
- 2025-02-07 filing 8-K items 3.01
- 2024-12-20 filing 424B5
- 2024-12-20 filing 8-K items 1.01,7.01,9.01
- 2024-12-20 filing 8-K items 7.01,9.01
- 2024-11-07 filing Quarterly report (10-Q)
- 2024-11-07 filing 8-K items 2.02,9.01
- 2024-10-02 filing SC 13D/A
- 2024-09-23 filing 8-K items 1.01,9.01
- 2024-09-06 filing SC 13D/A
- 2024-08-08 filing Quarterly report (10-Q)
- 2024-08-08 filing 8-K items 2.02,9.01
- 2024-06-13 filing 8-K items 5.07
- 2024-05-17 filing 8-K items 8.01
- 2024-05-14 filing Quarterly report (10-Q)
- 2024-05-14 filing 8-K items 2.02,9.01
- 2024-04-24 filing 8-K items 5.03,9.01
- 2024-04-24 filing ARS
- 2024-04-24 filing DEFA14A
- 2024-04-24 filing Proxy statement
- 2024-04-16 filing SC 13D/A
- 2024-03-26 filing S-8
- 2024-03-26 filing Annual report (10-K)
- 2024-03-26 filing 8-K items 2.02,9.01
- 2024-02-21 officer change 8-K items 5.02
- 2024-02-12 filing 8-K items 8.01
- 2024-01-09 filing 8-K items 7.01,9.01
- 2024-01-08 filing 8-K items 5.03,9.01
- 2023-12-13 filing 8-K items 7.01,8.01,9.01
- 2023-12-04 filing 8-K items 8.01,9.01
- 2023-11-07 filing Quarterly report (10-Q)
- 2023-11-07 filing 8-K items 2.02,9.01
- 2023-08-01 filing Quarterly report (10-Q)
- 2023-08-01 filing 8-K items 2.02,9.01
- 2023-06-14 filing 8-K items 5.07
- 2023-05-11 filing Quarterly report (10-Q)
- 2023-05-11 filing 8-K items 2.02,9.01
- 2023-04-24 filing DEFA14A
- 2023-04-24 filing ARS
- 2023-04-24 filing Proxy statement
- 2023-03-23 filing S-8
- 2023-03-23 filing Annual report (10-K)
- 2023-03-23 filing 8-K items 2.02,9.01
- 2023-03-10 filing 8-K items 7.01
- 2023-02-27 officer change 8-K items 5.02,9.01
- 2023-02-15 officer change 8-K items 5.02
- 2023-01-17 filing EFFECT
- 2023-01-13 filing CORRESP
- 2023-01-13 filing UPLOAD
- 2023-01-09 filing SC 13D/A
- 2023-01-06 filing S-3
- 2023-01-06 filing 8-K items 1.01,9.01
- 2023-01-06 filing 424B5
- 2022-11-07 filing 8-K items 1.01,9.01
- 2022-11-07 filing 424B5
- 2022-11-04 filing 8-K items 8.01,9.01
- 2022-11-04 filing Quarterly report (10-Q)
- 2022-11-03 filing 8-K items 2.02,9.01
- 2022-09-21 officer change 8-K items 5.02,9.01
- 2022-09-20 filing 3/A
- 2022-08-09 filing Quarterly report (10-Q)
- 2022-08-09 filing 8-K items 2.02,9.01
- 2022-06-17 filing 8-K items 5.07
- 2022-06-06 officer change 8-K items 5.02
- 2022-05-18 filing EFFECT
- 2022-05-17 filing POS AM
- 2022-05-05 filing Quarterly report (10-Q)
- 2022-05-04 filing 8-K items 2.02,9.01
- 2022-04-25 filing DEFA14A
- 2022-04-25 filing Proxy statement
- 2022-04-11 filing 8-K items 7.01,9.01
- 2022-03-01 filing 424B3
- 2022-03-01 filing S-8
- 2022-03-01 filing POS AM
- 2022-02-28 filing Annual report (10-K)
- 2022-02-28 filing POSASR
- 2022-02-25 officer change 8-K items 5.02
- 2022-02-04 filing S-3ASR
- 2022-01-11 filing 8-K items 1.01,9.01
- 2021-12-21 officer change 8-K items 5.02,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-16 (within 7 days) 10-Q filed
- 2026-10-29 (within 30 days) EFFECT filed
- 2026-10-29 (within 30 days) 424B3 filed
- 2026-10-27 (within 30 days) RW filed
- 2026-10-20 (older) S-1 filed
- 2026-10-20 (older) 8-K filed: Item 1.01 material agreement; Item 1.02 agreement terminated; Item 3.02 unregistered equity sale; Item 9.01 exhibits
- 2026-09-29 (older) 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-08-28 (older) 8-K filed: Item 3.01 delisting notice
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- No listing symbol is held for this company.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
4 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1826892 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | BCAB / OTC | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 851922320 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001826892 | SEC EDGAR / IRS |
possible match: matched by name only, not merged (2)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| EPA FRS id | 110070413889 (BIOATLA LLC) | name-exact: exact name match to 'BioAtla, Inc.' (no other entity shares the name) | EPA ECHO facilities |
| EPA FRS id | 110070487240 (BIOATLA LLC) | name-exact: exact name match to 'BioAtla, Inc.' (no other entity shares the name) | EPA ECHO facilities |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$59,607,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 11:14 UTC | Report an error |
| Total assets (at 2025-12-31) | $13,828,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 11:14 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | -$36,189,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 11:14 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $7,118,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 11:14 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 11:14 UTC | Report an error |
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 11:14 UTC | Report an error |
| State of incorporation | DE | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 11:14 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 11:14 UTC | Report an error |
| Business address | 11085 TORREYANA ROAD, SAN DIEGO, CA, 92121 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 11:14 UTC | Report an error |
| Exchanges | OTC | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 11:14 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$48,204,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 11:14 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $6,200,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 11:14 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001193125-26-462306
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$7,897,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-16 | 0001193125-26-462306 | 2026-11-20 11:14 UTC | Report an error |
| Cash and cash equivalents | $576,000 | at 2026-09-30 | 10-Q | 2026-11-16 | 0001193125-26-462306 | 2026-11-20 11:14 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-16 Filing 10-Q filed
- 2026-10-29 Filing EFFECT filed
- 2026-10-29 Filing 424B3 filed
- 2026-10-27 Filing RW filed
- 2026-10-20 Filing S-1 filed
- 2026-10-20 Filing 8-K filed: Item 1.01 material agreement; Item 1.02 agreement terminated; Item 3.02 unregistered equity sale; Item 9.01 exhibits
- 2026-09-29 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-08-28 Filing 8-K filed: Item 3.01 delisting notice
- 2026-08-13 Filing 10-Q filed
- 2026-07-16 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-06-03 Filing ARS filed
- 2026-06-03 Filing DEFA14A filed
- 2026-06-03 Filing DEF 14A filed
- 2026-05-15 Filing 10-Q filed
- 2026-04-29 Filing 10-K/A filed
- 2026-04-02 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-03-31 Filing S-8 filed
- 2026-03-31 Filing 10-K filed
- 2026-03-31 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure
- 2026-03-23 Filing 8-K filed: Item 5.02 officer or director change; Item 5.07 shareholder vote
- 2026-03-20 Filing 424B2 filed
- 2026-03-13 Filing 424B2 filed (PROSPECTUS SUPPLEMENT NO. 2)
- 2026-03-09 Filing 424B2 filed
- 2026-03-02 Filing DEFA14A filed
- 2026-03-02 Filing 8-K filed: Item 2.02 results of operations; Item 2.05 exit or disposal costs; Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
8-K item text, as filed (excerpts)
- 2026-10-20 8-K Item 1.01, Entry into a Material Definitive Agreement
On October 15, 2026 (the “Effective Date”), BioAtla, Inc. (the “Company”) entered into the Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd., a Cayman Islands exempt limited company (“Yorkville”), pursuant to which the Company has the right, but not the obligation, to sell to Yorkville up to $40.0 million of shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (such amount, the “Commitment Amount”), subject to certain limitations and conditions set forth in the SEPA, during the 36 months following the Effective Date (such shares, the “SEPA Shares”). Sales of the SEPA Shares to Yorkville and the timing of any such sales, if elected to be… the 8-K · retrieved 2026-11-20 11:14 UTC - 2026-10-20 8-K Item 1.02, Termination of a Material Definitive Agreement
On October 15, 2026, in connection with entering into the SEPA described in Item 1.01 of this Current Report, the Company terminated the Standby Equity Purchase Agreement, dated as of November 20, 2025 (the “Prior SEPA”), between the Company and Yorkville. Pursuant to the Prior SEPA, the Company had the right, but not the obligation, to sell to Yorkville up to $15.0 million of shares of Common Stock, subject to certain limitations and conditions set forth in the Prior SEPA. Prior to its termination, the Company sold an aggregate of 48,092 shares of Common Stock to Yorkville under the Prior SEPA for aggregate gross proceeds of approximately $0.4 million. At the time of termination, there… the 8-K · retrieved 2026-11-20 11:14 UTC - 2026-10-20 8-K Item 3.02, Unregistered Sales of Equity Securities
The information contained in Item 1.01 of this Current Report is incorporated by reference into this Item 3.02. the 8-K · retrieved 2026-11-20 11:14 UTC - 2026-08-28 8-K Item 3.01, Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on February 6, 2026, BioAtla, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) had determined to suspend the Company’s securities from Nasdaq (the “Delist Determination”) based upon (i) the Company’s non-compliance with the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) and (ii) the Company’s failure to demonstrate compliance with the $2.5 million stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), the latter notwithstanding the Company’s prior… the 8-K · retrieved 2026-11-20 11:14 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchBIOATLA LLC · exact name match to 'BioAtla, Inc.' (no other entity shares the name) · sx:epa:110070413889 Compare
- possible matchBIOATLA LLC · exact name match to 'BioAtla, Inc.' (no other entity shares the name) · sx:epa:110070487240 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 2 sources. Possible matches only.
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchBioAtla, Inc. · exact legal name · sx:ctgov:h4f2747aa246cb3a8 Compare
State licences (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchBIOATLA, LLC · exact name match to 'BioAtla, Inc.' (no other entity shares the name) · sx:elic:ctcred:1758353 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1826892.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001826892. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.